# Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

> **NCT02092909** · PHASE1,PHASE2 · TERMINATED · sponsor: **Idera Pharmaceuticals, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** IMO-8400

## Key facts

- **NCT ID:** NCT02092909
- **Lead sponsor:** Idera Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2017-04
- **Final completion:** 2017-11
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02092909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02092909, "Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02092909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*